Elizabeth H.z. Thompson - 12 Aug 2024 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role
EVP, Head of Research & Dev
Signature
/s/ Jennifer J. Rhodes, Attorney-in-Fact
Issuer symbol
ACAD
Transactions as of
12 Aug 2024
Net transactions value
$0
Form type
4
Filing time
13 Aug 2024, 18:05:04 UTC
Previous filing
02 Jul 2024
Next filing
02 Oct 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACAD Stock Option (Right to Buy) Award $0 +324,582 $0.000000 324,582 12 Aug 2024 Common Stock 324,582 $15.29 Direct F1
transaction ACAD Restricted Stock Units Award $0 +64,544 $0.000000 64,544 12 Aug 2024 Common Stock 64,544 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the Stock Option will vest and become exercisable on July 29, 2025. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
F2 Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
F3 50% of the restricted stock units vest on July 29, 2026 and 25% vest on each of July 29, 2027 and July 29, 2028.